There were 359 press releases posted in the last 24 hours and 437,700 in the last 365 days.

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.

Stifel 2015 Healthcare Conference
Wednesday, November 18, 2015 at 9:30 a.m. ET in New York, NY

Goldman Sachs US Emerging & SMID Cap Growth Conference
Thursday, November 19, 2015 at 8:40 a.m. ET in New York, NY

The audio webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com.  A replay of the presentation will be posted on the Momenta website approximately one hour after the event and will be available for two weeks following the presentation.

About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.


Contact: 
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.